芦司他汀治疗低危骨髓增生异常综合征患者贫血的长期疗效与安全性:II期PACE-MDS研究
PACE-MDS研究纳入108例低危骨髓增生异常综合征(LR-MDS)患者,报告芦司他汀长期安全性与疗效。主要终点为安全性,未出现新安全信号;红细胞血液学改善(HI-E)率为53.7%。基线促红细胞生成素水平较低及红系晚期与早期祖细胞比值较高与HI-E相关。
要点
- 芦司他汀中位暴露315天(范围21-1,934天),未出现新安全信号。
- HI-E总发生率为53.7%,非环形铁粒幼细胞患者为36.4%,非输血依赖患者为70.6%。
- 中性粒细胞血液学改善和血小板血液学改善发生率分别为33.3%和9.5%。
核心结论
- 芦司他汀在低危骨髓增生异常综合征各亚型中显示临床活性,包括未经治疗的MDS-RS患者,可作为未来试验的平台。
研究设计与样本
- II期PACE-MDS研究,纳入108例低危骨髓增生异常综合征患者,其中44例非环形铁粒幼细胞患者和34例非输血依赖或既往未经治疗患者;主要终点为安全性,次要终点包括红细胞、中性粒细胞和血小板血液学改善率,探索性终点包括红系生物标志物定量和突变数据。
主要发现
- 芦司他汀中位暴露时间为315天(范围21-1,934天),未出现新安全信号。
- 红细胞血液学改善(HI-E)发生于53.7%的患者,包括36.4%的非环形铁粒幼细胞患者和70.6%的非输血依赖患者。
- 中性粒细胞血液学改善和血小板血液学改善分别发生于33.3%和9.5%的患者。
- 骨髓晚期与早期祖细胞比值在HI-E缓解时几乎增加三倍,与环形铁粒幼细胞状态无关。
- 非环形铁粒幼细胞患者基线促红细胞生成素水平较低(69.6 vs 623.3 IU/L;P=0.0077)及环形铁粒幼细胞患者红系晚期与早期祖细胞比值较高(10.44 vs 4.48;P=0.0106)与HI-E相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Luspatercept has high clinical activity in patients with transfusion-dependent lower-risk myelodysplastic syndromes (LR-MDS) and ring sideroblasts (RS) relapsed or refractory to erythropoietin. We report long-term luspatercept safety and efficacy in 108 patients with LR-MDS in the PACE-MDS study, including 44 non-RS and 34 non-transfusion-dependent or previously untreated patients. The primary end point was safety. Secondary end points included rates of hematologic improvement (HI) erythroid (HI-E), HI neutrophil, and HI platelet. Exploratory end points included erythropoiesis biomarker quantitation and mutation data. Median duration of luspatercept exposure was 315 days (range, 21-1,934 days). No new safety signals emerged. HI-E was observed in 53.7% of patients, including 36.4% of non-RS and 70.6% of non-transfusion-dependent patients. HI neutrophil and HI platelet were observed in 33.3% and 9.5% of patients, respectively. An almost three-fold increase in bone marrow late to early progenitor cell ratio accompanied HI-E response, irrespective of RS status. Lower baseline erythropoietin levels in non-RS patients (69.6 v 623.3 IU/L; P = .0077) and higher late to early erythroid progenitor cell ratio (10.44 v 4.48; P = .0106) in RS patients were associated with HI-E. This study highlights luspatercept's effects across LR-MDS subtypes, including untreated MDS-RS, serving as a platform for future trials.
引用
- Platzbecker U, Götze KS, Kiewe P, et al. Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study. J Clin Oncol. 2022. PMID: 35998303. doi:10.1200/JCO.21.02476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。